Molecular Weight(MW): 206.03
Etidronate is a non-aminobisphosphonate, show protein tyrosine phosphatase (PTP) inhibitory activity, used for the treatment of Paget's disease and the prevention of heterotopic ossification.
Purity & Quality Control
Choose Selective phosphatase Inhibitors
|Description||Etidronate is a non-aminobisphosphonate, show protein tyrosine phosphatase (PTP) inhibitory activity, used for the treatment of Paget's disease and the prevention of heterotopic ossification.|
Etidronate inhibits directly osteoclastic bone-resorbing activity by pit assay. Etidronate also directly induces apoptosis and disrupts actin rings in osteoclasts. 
|In vivo||Etidronate, when administered s.c. repeatedly at 10 or 40 mg/kg/day, gradually suppresses the adjuvant-induced allodynia In the rats with adjuvant arthritis, as assessed by 10-g von Frey hair. Etidronate (10-40 mg/kg/day) suppresses the adjuvant-induced mechanical allodynia in rat hindpaw. Etidronate (5–10 mg/kg/day) dose-dependently prevents the decrease in bone mineral density (BMD) in the proximal tibia of the arthritic rats.  Etidronate inhibits the histidine decarboxylase induction, but not the other inflammatory reactions induced by alendronate. Etidronate (unlike clodronate) also inhibits alendronate-induced BP-line formation in mice (even at 40 mmol/kg). Etidronate (160 mmol/kg) also inhibits the physicochemical changes in the tibia induced by six, weekly injections of alendronate.  Etidronate (10 mg/kg) combined with Calcitriol after subtotal nephrectomy (SNx) significantly inhibits thoracic and abdominal aortic calcification 3 weeks after the operation in rats.  Etidronate (5 mg/kg or 10 mg/kg) significantly reduces the thoracic and abdominal aortic calcification induced by calcitriol in the renal failure rat. Etidronate (5 mg/kg or 10 mg/kg) also reduces the dysfunction in aortic contraction. Etidronate (5 mg/kg) reverses the reduction in the aortic expression of matrix Gla protein mRNA observed in nephrectomized rats. |
-  Hiroi-Furuya E, et al. Calcif Tissue Int, 1999, 64(3), 219-223.
-  Kawabata A, et al. Neuropharmacology, 2006, 51(2), 182-190.
-  Funayama H, et al. Calcif Tissue Int, 2005, 76(6), 448-457.
|In vitro||Water||41 mg/mL (199.0 mM)|
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).
Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )
* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).
Molecular Weight Calculator
Enter the chemical formula of a compound to calculate its molar mass and elemental composition:
Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2
Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
Clinical Trial Information
|NCT Number||Recruitment||Conditions||Sponsor/Collaborators||Start Date||Phases|
|NCT01077817||Completed||Esophageal Cancer|Squamous Cell Carcinoma|Adenocarcinoma||Merck Sharp & Dohme Corp.|World Health Information Science Consultants LLC||February 26 2010||--|
|NCT00376662||Completed||Osteoporosis||British Thoracic Society||August 1992||Phase 4|
|NCT01585402||Recruiting||Arterial Calcification|CD73 Deficiency||National Heart Lung and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC)||April 11 2012||Phase 2|
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.